title: Postprandial lipemia, fenofibrate and coronary artery disease.
abstract: This report describes the response of patients with severe coronary artery disease to a dynamic fat load test and monitors the change induced by fenofibrate therapy. The presence of disease was associated with prolonged and exaggerated hypertriglyceridemia following the meal and with lower basal HDL cholesterol and HDL subfraction masses. A further indicator of risk was the persistence of increased amounts of retinyl palmitate in the plasma of severely affected individuals 24 h after its ingestion with the meal. These observations are consistent with the proposal that the clearance of chylomicrons and their remnants is impaired in coronary atherosclerosis. Fenofibrate reduced alimentary lipemia following the fat load in both normo- and hypercholesterolemic subjects. This was associated with a 10% rise in plasma HDL cholesterol levels. The improvement in chylomicron catabolism probably derived from a 37% increase (P less than 0.001) in lipoprotein lipase activity induced by fenofibrate. Hepatic lipase on the other had was only slightly affected by treatment.
authors.affiliation: Department of Medical Cardiology, Royal Infirmary, Glasgow, U.K.
authors.forename: H S
authors.initials: HS
authors.lastname: Simpson
authors.forename: C M
authors.initials: CM
authors.lastname: Williamson
authors.forename: T
authors.initials: T
authors.lastname: Olivecrona
authors.forename: S
authors.initials: S
authors.lastname: Pringle
authors.forename: J
authors.initials: J
authors.lastname: Maclean
authors.forename: A R
authors.initials: AR
authors.lastname: Lorimer
authors.forename: F
authors.initials: F
authors.lastname: Bonnefous
authors.forename: Y
authors.initials: Y
authors.lastname: Bogaievsky
authors.forename: C J
authors.initials: CJ
authors.lastname: Packard
authors.forename: J
authors.initials: J
authors.lastname: Shepherd
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D004041:Dietary Fats / Q000008:administration & dosage; D004224:Diterpenes; D011345:Fenofibrate / Q000627:therapeutic use*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008049:Lipase / Q000097:blood; D008055:Lipids / Q000097:blood*; D008071:Lipoprotein Lipase / Q000097:blood; D008099:Liver / Q000201:enzymology; D008875:Middle Aged; D000084562:Retinyl Esters; D014280:Triglycerides / Q000097:blood; D014801:Vitamin A / Q000031:analogs & derivatives / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D015243:Cholesterol, VLDL; D004041:Dietary Fats; D004224:Diterpenes; D008055:Lipids; D000084562:Retinyl Esters; D014280:Triglycerides; D014801:Vitamin A; C014794:retinol palmitate; D006493:Heparin; D002784:Cholesterol; D008049:Lipase; D008071:Lipoprotein Lipase; D011345:Fenofibrate